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Abstract
Background and objective—Chronic obstructive pulmonary disease is characterized by an 
inflammatory state of uncertain significance. The objective of this study was to examine the 
association between elevated inflammatory marker count (white blood cell count, C-reactive 
protein and fibrinogen) on all-cause mortality in a national sample of US adults with obstructive 
lung function (OLF).
Methods—Data for 1144 adults aged 40–79 years in the National Health and Nutrition 
Examination Survey III Linked Mortality Study were analysed. Participants entered the study from 
1988 to 1994, and mortality surveillance was conducted through 2006. White blood cell count and 
fibrinogen were dichotomized at their medians, and C-reactive protein was divided into >3 and ≤3 
g/L. The number of elevated inflammatory markers was summed to create a score of 0–3.
Results—The age-adjusted distribution of the number of elevated inflammatory markers differed 
significantly among participants with normal lung function, mild OLF, and moderate or worse 
OLF. Of the three dichotomized markers, only fibrinogen was significantly associated with 
mortality among adults with any OLF (maximally adjusted hazard ratio 1.49; 95% confidence 
interval (CI): 1.17–1.91). The maximally adjusted hazard ratios for having 1, 2 or 3 elevated 
markers were 1.17 (95% CI: 0.71–1.94), 1.44 (95% CI: 0.89–2.32) and 2.08 (95% CI: 1.29–3.37), 
respectively (P = 0.003).
Conclusions—An index of elevated inflammatory markers predicted all-cause mortality among 
adults with OLF.
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Chronic obstructive pulmonary disease (COPD) accounted for 138 578 deaths in the United 
States in 2011.1 Although deaths from COPD decreased globally from 3.1 million in 1990 to 
2.9 million in 2010, COPD rose from the fourth to the third leading cause of death in 2010.2 
In terms of years of life lost, COPD decreased from seventh place in 1990 to ninth place in 
2010. Thus, understanding the risk factors for this high mortality among people with COPD 
is critical to developing strategies to reduce the high mortality from this disease.
COPD has been shown to be accompanied by an inflammatory component.3 This 
inflammation may be inherent to the disease itself, a reflection of the comorbidities that 
often accompany this disease, or due to continued exposure to agents such as tobacco that 
cause inflammation. Although the consequences of this inflammation on morbidity and 
mortality are still unfurling, studies have linked various inflammatory parameters to 
mortality and exacerbations in people with COPD.4-10 Because of limited evidence about 
how risk for mortality among people with COPD varies in function of the number of 
inflammatory markers, the objective of this study was to examine the associations between 
the count of elevated inflammatory markers and all-cause mortality in US adults with 
obstructive lung function (OLF).
METHODS
Data from the Third National Health and Nutrition Examination Survey (NHANES III) 
Linked Mortality Study were used to conduct the present study.11 From 1988 to 1994, a 
representative sample of the civilian non-institutionalized population in the United States 
was selected by using a stratified multistage probability design. Once participants provided 
their informed consent, they were interviewed in their homes and, for those who attended an 
examination in the mobile examination center, completed additional questionnaires, received 
various examinations, and provided blood and urine specimens. The response rates were 
86% for the interview and 78% for the examination. Because we analysed public-use data, 
our study was exempt from institutional review.
The vital status of participants was tracked through a probabilistic match of participants’ 
information with National Death Index death certificate records. If participants’ information 
could not be matched, they were presumed to be alive.
C-reactive protein was measured by using latex-enhanced nephelometry on a Behring 
Nephelometer Analyzer System (Behring Diagnostics Inc., Somerville, NJ, USA). The 
lower detection limit was 3.0 g/L, and C-reactive protein was divided into >3 and ≤3 g/L. 
Concentrations of fibrinogen concentration were measured on a Coagamate XC Plus 
automated coagulation analyser (Organon Teknika, Durham, NC, USA). Fibrinogen was 
analysed as a dichotomous variable (split at the median value) and as quartiles. White blood 
cell count was determined on a Coulter Counter Model S-PLUS JR (Coulter Electronics, 
Hialeah, FL, USA). White blood cell count was also analysed as a dichotomous variable 
(split at the median value) and as quartiles. The dichotomized variables were assigned a 
value of 1 or 0 where 1 represented elevated levels of these markers. The dichotomized 
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markers were summed to create an elevated inflammatory marker count score that ranged 
from 0 to 3.
The procedures used to conduct spirometry are detailed elsewhere.12 Post-bronchodilator 
testing was not performed. We used equations published by Hankinson and colleagues to 
calculate predicted forced expiratory volume in 1 s (FEV1) and forced vital capacity 
(FVC).13 Normal lung function was defined as a ratio of FEV1/FVC ≥ 0.70 and FVC ≥ 80%, 
mild OLF was defined as a ratio of FEV1/FVC < 0.70 and FEV1 ≥ 80%, moderate OLF was 
defined as a ratio of FEV1/FVC < 0.70 and FEV1 50 to <80% predicted, and severe to very 
severe OLF was defined as a ratio of FEV1/FVC < 0.70 and FEV1 < 50% predicted. We 
excluded participants with restrictive lung function (FEV1/FVC ≥ 0.70 and FVC < 80% 
predicted) from the analyses. For the mortality analyses, we combined participants with 
mild, moderate or severe COPD to improve sample size. For analyses examining levels of 
inflammatory markers by pulmonary function status, we created three groups: normal lung 
function, mild OLF and moderate-severe OLF.
We included the following covariates: age, gender, self-reported race or ethnicity (white, 
African-American and other), educational level (<12, 12 and >12 years), smoking status 
(current, former, never), frequency of alcohol use (times in past 30 days), leisure-time 
physical activity (vigorous, moderate, light, sedentary), systolic blood pressure, high-density 
lipoprotein cholesterol, non-high-density lipoprotein cholesterol, body mass index, urinary 
albumin-creatinine ratio (UACR), self-reported health status, diabetes (self-report or HbA1c 
≥ 6.5%), and histories of myocardial infarction, stroke and cancer. Because these covariates 
have been shown to be related to inflammation and mortality, they were included in our 
analyses.14-19
Men and non-pregnant women aged 40–79 years who had a spirometric examination in the 
mobile examination centre, reproducible FEV1 and FVC results, and a complete set of data 
were included in the analyses. To improve its distributional properties, urinary albumin-
creatinine ratio (UACR) was transformed to the −0.1 power to better approximate a normal 
distribution. Direct age adjustment was done by using the projected year 2000 US 
population for adults aged 40–79 years. Differences in means and categorical variables by 
mortality status were tested by t-tests and chi-square tests. Differences in means and 
categorical variables by elevated inflammatory marker count were tested by Satterthwaite 
adjusted F and chi-square tests in regression analyses. The associations between 
inflammatory markers and all-cause mortality were examined with proportional hazards 
analysis. Follow-up time was calculated for each participant from the date of the baseline 
examination to the date of death for deceased participants or to 31 December 2006 for 
survivors. We present the results for five proportional hazards models incorporating various 
levels of adjustment: model 1 is adjusted for age; model 2 is adjusted for variables in model 
1 plus gender, race or ethnicity, and education; model 3 is adjusted for variables in model 2 
plus smoking status, alcohol use and leisure-time physical activity; model 4 is adjusted for 
variables in model 3 plus systolic blood pressure, high-density lipoprotein cholesterol, non-
high-density lipoprotein cholesterol, body mass index and urinary albumin-creatinine ratio; 
and model 5 is adjusted for variables in model 4 plus health status, diabetes, history of 
myocardial infarction, history of stroke, history of cancer and severity of COPD. We used 
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the statistical programs SAS (SAS Institute Inc., Cary, NC, USA) and SUDAAN (Research 
Triangle Institute, Research Triangle Park, NC, USA) to conduct our analyses.
RESULTS
Of the 8486 men and non-pregnant women aged 40–79 years who attended an examination 
and were eligible for follow up, 640 participants with self-reported asthma or missing 
asthma status were excluded leaving 7240 participants with values for FEV1 and FVC. After 
limiting the sample to adults with acceptable spirometric manoeuvres, 6539 participants 
remained. Further reductions for missing values for study variables reduced the sample to 
5584, of whom 1144 participants had OLF (629 with mild OLF, 429 with moderate OLF 
and 86 with severe OLF). The 1144 participants included 721 men, 423 women, 714 whites, 
219 African-Americans, 185 Mexican-Americans, and 26 participants of another race or 
ethnicity. The mean age was 61 years.
During a mean follow up of 12.5 years, 538 participants died. Numerous differences in study 
variables existed between survivors and decedents (Table 1). Decedents had significant 
higher mean concentrations of age-adjusted fibrinogen, not significantly higher levels of 
white blood cell count, and a significantly higher age-adjusted percentage of participants 
with a concentration of C-reactive protein >3 g/L. The age-adjusted distribution of elevated 
inflammatory marker count also differed significantly between decedents and participants 
who survived. Numerous differences of unadjusted means or percentages of study variables 
across elevated inflammatory marker count were present (Table 2).
At baseline, participants with mild OLF had a higher age-adjusted mean concentration of 
fibrinogen than those with normal lung function (Table 3). Participants with moderate to 
very severe OLF had greater means of white blood cell count and fibrinogen as well as a 
higher percentage of elevated concentration of C-reactive protein than either those with 
normal lung function or mild OLF. Furthermore, the age-adjusted distribution of the number 
of elevated inflammatory markers differed significantly among the three groups (Fig. 1).
After adjustment for age, gender, race or ethnicity, and educational status, dichotomized 
levels of inflammatory markers were significantly associated with all-cause mortality 
(Supplementary Table S1). Even after adjustment for smoking status as well as alcohol use 
and physical activity (model 3), C-reactive protein and fibrinogen were significantly 
associated with mortality. With additional adjustment for systolic blood pressure, high-
density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, body mass index, 
urinary albumin-creatinine ratio, health status, diabetes, history of myocardial infarction, 
history of stroke, history of cancer and severity of COPD, however, only elevated 
concentrations of fibrinogen were significantly associated with mortality. The associations 
of quartiles for white blood cell count and fibrinogen followed a similar pattern 
(Supplementary Table S2).
The count of elevated inflammatory markers was significantly associated with all-cause 
mortality (Supplementary Table S2). Among those with elevated markers for all three 
variables, the maximally adjusted hazard ratio was 2.08 (95% confidence interval (CI): 
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1.29–3.37). Although the association seemed particularly strong among adults with 
moderate-severe OLF (Fig. 2), there was no statistical evidence to support a difference in the 
associations of elevated inflammatory marker count with all-cause mortality between 
participants with mild OLF and those with moderate-severe OLF (P interaction = 0.576). 
Hazard ratios comparing a count of 3 with a count of 0 were 1.65 (95% CI: 0.85–3.20) 
among participants with mild OLF and 2.81 (95% CI: 1.76–4.50) among participants with 
moderate to severe OLF. Furthermore, there was no evidence that the associations between 
dichotomized C-reactive protein (P interaction = 0.769), white blood cell count (P 
interaction = 0.706) and fibrinogen (P interaction = 0.464), and mortality differed by COPD 
severity.
There was also no statistical evidence that the hazard ratios differed among those with 
normal lung function and OLF for inflammatory parameter count (P interaction = 0.954), 
dichotomized C-reactive protein (P interaction = 0.341), white blood cell count (P 
interaction = 0.531) and fibrinogen (P interaction = 0.549).
DISCUSSION
In a national sample of US adults, our results showed that adults with OLF, particularly 
those with moderate to very severe OLF, had higher levels of white blood cell count and 
fibrinogen as well as a higher percentage of elevated C-reactive protein than participants 
with normal lung function. Furthermore, the number of elevated inflammatory markers was 
significantly associated with all-cause mortality among adults with OLF.
Our analyses indicated that white blood cell count and concentrations of elevated C-reactive 
protein were weakly associated with all-cause mortality and that elevated concentrations of 
fibrinogen were modestly associated with all-cause mortality. Previous studies have shown 
that concentrations of white blood cell count, C-reactive protein and fibrinogen are 
significant predictors of all-cause mortality in adults with COPD or OLF.4-10 In addition, 
interleukin-6, neutrophils, CC chemokine ligand-18/pulmonary and activation-regulated 
chemokine, surfactant protein D and interleukin-8 have been shown to be associated with 
mortality in adults with COPD.9 Furthermore, a panel of inflammatory biomarkers predicted 
mortality in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
Endpoints study.9 In a Danish study, the associations among white blood cell count, C-
reactive protein and fibrinogen on exacerbations among 6574 adults with COPD were 
investigated.20 The risk for exacerbations increased progressively as the number of elevated 
inflammatory markers increased.
The implications of the studies that have described associations between inflammatory 
markers and mortality remain uncertain in part because it is unclear whether these 
inflammatory markers represent true risk factors or are risk markers. Furthermore, the 
source of these elevated inflammatory markers is possibly attributable to COPD itself, from 
continued exposure to toxic agents such as cigarette smoke, or to comorbidities that are 
common among patients with COPD. These markers can potentially be used to identify 
groups of patients who are at increased risk for early mortality. Because no clear treatments 
to temper inflammation in patients currently exist, optimal treatment of patients with 
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elevated inflammatory markers may possibly reduce their risk. Statins may reduce 
concentrations of C-reactive protein,21-23 and some studies suggested that treatment with 
statins was potentially useful to reduce morbidity and mortality in patients with COPD.24-28 
The hope that treatment with statins might be particularly beneficial in patients with COPD 
was dashed when a recent trial failed to find a benefit from statin treatment on 
exacerbations.29 Aspirin and other non-steroidal anti-inflammatory drugs may also reduce 
inflammatory parameters such as C-reactive protein,21,30,31 but their use in patients with 
COPD remains to be established. Corticosteroids also reduce inflammation,32,33 but the 
possible effects on inflammation from chronic use of oral steroids have to be balanced 
against their side effects. Although some studies suggest that inhaled corticosteroids may 
reduce inflammatory parameters such as C-reactive protein,33,34 clinical trials have 
produced mixed results.35-37
Several limitations should be noted. First, the sample size of this study and particularly that 
of adults with moderate to very severe OLF limited the ability to detect small to moderate 
associations, examine interactions or perform other stratified analyses such as gender-
specific or race-specific analyses. Second, post-bronchial testing was not performed raising 
the possibility that participants who were identified as having OLF may have had asthma. 
We tried to minimize the possible inclusion of participants with asthma by excluding 
younger participants who are more likely to have asthma and by excluding those with self-
reported asthma. Nevertheless, an unknown number of adults with asthma may have been 
included. Third, concentrations of C-reactive protein were assayed with a low sensitivity test 
that prevented us from exploring the association between the full range of C-reactive protein 
and all-cause mortality. Fourth, clinical information on the course of the disease in these 
participants was not available. Fifth, participants were not subject to additional examinations 
between the baseline examination and the establishment of their vital status, which might 
have allowed the examination in changes of levels of inflammatory markers on mortality. 
Furthermore, the possible impact of changes in covariate status, such as smoking status, on 
the associations of inflammatory markers with mortality could not be modelled. Finally, the 
possibility of residual confounding due to incomplete characterization or exclusion of 
potential confounders must also be acknowledged.
In conclusion, the number of elevated inflammatory markers was significantly associated 
with all-cause mortality in a national sample of adults with OLF. These results suggest that 
three readily measured inflammatory markers, namely white blood cell count, C-reactive 
protein and fibrinogen, may be useful in characterizing patients at increased risk for 
premature death. Additional studies examining the range of inflammatory markers on 
morbidity and mortality may help to characterize the risks for various adverse outcomes and 
pave the way for advances in therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The findings and conclusions in this article are those of the authors and do not necessarily represent the official 
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SUMMARY AT A GLANCE
Among adults with OLF in the United States, the associations among C-reactive protein, 
fibrinogen and leukocyte count and mortality were examined. The hazard ratios for 
having 1, 2 or 3 elevated markers were 1.17 (95% CI: 0.71–1.94), 1.44 (95% CI: 0.89–
2.32) and 2.08 (95% CI: 1.29–3.37), respectively.
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Age-adjusted percentages (95% confidence interval) for number of elevated inflammatory 
markers among adults aged 40–79 years, by pulmonary function status, National Health and 
Nutrition Examination Survey III 1988–1994. P Cochran–Mantel–Haenszel test for mild 
obstructive lung function versus normal lung function = 0.094; for moderate + obstructive 
lung function versus normal lung function <0.001; for moderate versus mild obstructive lung 
function <0.001.
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Maximally adjusted hazard ratios (95% confidence interval) for all-cause mortality by 
number of elevated inflammatory marker among adults aged 40–79 years with mild or 
moderate to very severe obstructive lung function, National Health and Nutrition 
Examination Survey III Linked Mortality Study 1988–1994 to 2006.
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Table 1
Age-adjusted baseline means (standard errors) and percentages (standard errors) of study variables among 
adults aged 40–79 years with obstructive lung function, by mortality status, National Health and Nutrition 
Examination Survey III (1988–1994)
Mortality status
P-valueDead (n = 538) Alive (n = 606)
Age (years) 66.4 (0.5) 57.2 (0.6) <0.001
Education (years) 11.6 (0.4) 12.5 (0.2) 0.066
Frequency of drinks (per month) 10.1 (1.9) 12.0 (1.2) 0.353
Systolic blood pressure (mm Hg) 131.6 (1.8) 124.7 (0.9) 0.002
High-density lipoprotein cholesterol (mmol/L) 1.2 (<0.1) 1.3 (<0.1) 0.108
Non-high-density lipoprotein cholesterol (mmol/L) 4.4 (0.2) 4.3 (<0.1) 0.592
Body mass index (kg/m2) 25.7 (0.8) 26.6 (0.3) 0.230
Albumin-creatinine ratio (mg/g) 10.2 (1.1) 6.0 (0.3) <0.001
Glomerular filtration rate (mL/min/1.73 m2) 88.1 (1.7) 88.5 (0.9) 0.817
Forced expiratory volume in 1 s (mL) 2409.1 (107.3) 2679.2 (52.6) 0.024
Forced vital capacity (mL) 3895.4 (130.5) 4143.0 (68.4) 0.089
FEV1/FVC 0.61 (0.01) 0.64 (<0.01) 0.001
Fibrinogen (g/L) 3.4 (0.1) 3.0 (0.1) 0.001
White blood cells (109/L) 8.2 (0.3) 7.5 (0.1) 0.074
Men (%) 71.9 (3.6) 58.2 (2.9) 0.002
White (%) 86.1 (2.9) 87.5 (1.2) 0.635
High school graduate or higher (%) 67.1 (4.2) 76.9 (2.6) 0.038
Current smoker (%) 59.8 (6.8) 38.4 (2.5) 0.005
Moderate-vigorous leisure-time physical activity (%) 33.8 (4.4) 44.2 (3.8) 0.122
Vitamin or mineral supplement use during past 30 days (%) 37.6 (6.2) 43.3 (2.6) 0.371
C-reactive protein >3 g/L (%) 41.7 (5.6) 28.0 (2.8) 0.045
≥Good health status (%) 77.7 (3.8) 88.2 (1.6) 0.008
Diabetes (%) 8.5 (1.4) 6.1 (1.1) 0.229
History of myocardial infarction (%) 8.0 (2.8) 4.6 (1.5) 0.271
History of stroke (%) 5.2 (2.4) 1.7 (0.7) 0.169
History of cancer (%) 11.1 (3.0) 2.3 (0.6) 0.005
Number inflammatory markers (%) <0.001
 0 17.7 (7.0) 30.1 (2.9) —
 1 25.5 (3.8) 35.8 (3.6) —
 2 28.9 (4.4) 21.7 (2.3) —
 3 28.0 (5.4) 12.4 (2.0) —
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